DCF Advisers, LLC - Q1 2020 holdings

$153 Million is the total value of DCF Advisers, LLC's 67 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .

 Value Shares↓ Weighting
GLD  SPDR GOLD TRUST$9,623,000
+3.6%
65,0000.0%6.30%
+7.0%
AMD  ADVANCED MICRO DEVICES INC$3,866,000
-0.8%
85,0000.0%2.53%
+2.5%
C  CITIGROUP INC$3,159,000
-47.3%
75,0000.0%2.07%
-45.5%
IAU  ISHARES GOLD TRUSTishares$3,014,000
+3.9%
200,0000.0%1.97%
+7.4%
SGEN  SEATTLE GENETICS INC$1,961,000
+1.0%
17,0000.0%1.28%
+4.3%
NKTR  NEKTAR THERAPEUTICS$768,000
-17.2%
43,0000.0%0.50%
-14.6%
NLOK  NORTONLIFELOCK INC$748,000
-26.7%
40,0000.0%0.49%
-24.4%
AAPL  APPLE INC$636,000
-13.4%
2,5000.0%0.42%
-10.5%
BIF  BOULDER GROWTH & INCOME FD I$541,000
-21.9%
58,7830.0%0.35%
-19.4%
INTC  INTEL CORP$541,000
-9.7%
10,0000.0%0.35%
-6.6%
NOK  NOKIA CORPsponsored adr$465,000
-16.5%
150,0000.0%0.30%
-13.9%
SGMO  SANGAMO THERAPEUTICS INC$343,000
-23.9%
53,9000.0%0.22%
-21.7%
NXPI  NXP SEMICONDUCTORS N V$290,000
-34.8%
3,5000.0%0.19%
-32.6%
BGY  BLACKROCK ENHANCED INTL DIV$54,000
-23.9%
12,0000.0%0.04%
-22.2%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTRA-CELLULAR THERAPIES INC16Q3 202310.2%
MICRON TECHNOLOGY INC16Q3 20236.7%
ALPHABET INC16Q3 20235.8%
ABBVIE INC16Q3 20237.9%
REGENERON PHARMACEUTICALS16Q3 20235.5%
ARGENX SE16Q3 20236.4%
SPDR GOLD TRUST16Q3 20236.6%
XENCOR INC16Q3 20234.1%
BK OF AMERICA CORP16Q3 20235.4%
ORACLE CORP16Q3 20233.2%

View DCF Advisers, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-09
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-11
13F-HR2022-05-13
13F-HR2022-02-10

View DCF Advisers, LLC's complete filings history.

Compare quarters

Export DCF Advisers, LLC's holdings